retrogenix cell microarray (Charles River Laboratories)
86
Structured Review
Charles River Laboratories
retrogenix cell microarray
Retrogenix Cell Microarray, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Microarrays/cell+microarray+screen+technology/pmc13276592-382-1-1
Average 86 stars, based on 1 article reviews
Retrogenix Cell Microarray, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/Microarrays/cell+microarray+screen+technology/pmc13276592-382-1-1
Average 86 stars, based on 1 article reviews
retrogenix cell microarray - by Bioz Stars,
2026-09
86/100 stars
Images
1) Product Images from "Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity"
Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity
Journal: iScience
doi: 10.1016/j.isci.2026.116022
Figure Legend Snippet: BNT351 shows comparable target affinity to 1-18 and no off-target binding (A) Left: the binding affinity of BNT351 and 1-18 to the stabilized HIV-1 envelope protein trimer (SOSIP BG505.664 ) by SPR (mean and individual values of triplicate measurements). Also see A. Right: binding of BNT351 and 1-18 to SOSIP BG505.664 by ELISA (mean ± standard deviation of triplicate measurements). (B) BNT351’s off-target binding was assessed by Retrogenix Cell Microarray Technology platform. Interactions identified during the library screen with ∼6,500 human proteins are shown. Also, see . Interaction with pepsinogen C (PGC) that appeared to be specific was re-tested by flow cytometry with HEK293 cells transfected with PGC. HEK293 cells transfected with FcγRIIIa and FcεRIg were used as a positive control. Duplicate measurements are shown for flow cytometry.
Techniques Used: Binding Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation, Microarray, Flow Cytometry, Transfection, Positive Control
Related Articles
Microarray:Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. Each binding arm of JNJ-80948543 was evaluated for binding specificity in the Retrogenix® Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. The individual CD79b, CD20 and CD3 molecules were screened for binding specificity using the Retrogenix® Article Title: CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses Article Snippet: .. Screening for off-target binding of Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models Article Snippet: For all in vivo studies, female nonobese diabetic (NOD) severe combined immunodeficiency (scid) gamma (NSG; The Jackson Laboratory) mice aged ∼5 to 8 weeks and weighing ∼20 g were used. .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using the Retrogenix Clinical Proteomics:Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Membrane:Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity Article Snippet: .. The Binding Assay:Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. Each binding arm of JNJ-80948543 was evaluated for binding specificity in the Retrogenix® Article Title: Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma Article Snippet: MFI values were extracted, background-subtracted using secondary antibody control wells, and plotted in Prism (GraphPad, version 10.4) using a four-parameter nonlinear regression. .. Off-target binding interactions of ARC101 with human membrane and secreted proteins were assessed using Article Title: Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. Article Snippet: .. The individual CD79b, CD20 and CD3 molecules were screened for binding specificity using the Retrogenix® Article Title: CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses Article Snippet: .. Importantly, as specificity can often be challenging for antibodies against GPCRs, a Article Title: CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses Article Snippet: .. Screening for off-target binding of Article Title: Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models Article Snippet: For all in vivo studies, female nonobese diabetic (NOD) severe combined immunodeficiency (scid) gamma (NSG; The Jackson Laboratory) mice aged ∼5 to 8 weeks and weighing ∼20 g were used. .. The binding specificity of the individual BCMA and GPRC5D antibodies were assessed using the Retrogenix |